Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
View Patent ↗Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
1. A medical device comprising:
an implantable structure;
a basecoat layer affixed to the implantable structure, the basecoat layer comprising a first polymeric material;
trichostatin A, in thereapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury, the trichostatin A being incorporated into the basecoat layer, the concentration of trichostatin A being less than 100 nano molar;
rapamycin, in therapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury, the rapamycin being incorporated into the basecoat layer, the rapamycin and the trichostatin A potentiating each others effectiveness; and polymeric material affixed to the basecoat layer to control the elution rate of the trichostatin A and the rapamycin, the topcoat layer comprising the second polymeric material and the basecoat layer comprising the first polymeric material being immiscible and chemically incompatible polymeric materials, wherein the first polymeric material includes a fluoropolymer comprising a copolymer of polyvinylidenefluoride-co-hexafluoropropylene and the second polymeric material includes at least 150 micrograms of an acrylate comprising poly(n-butylmethacrylate) layer wherein the basecoat and the topcoat are affixed as separate and distinct layers upon each other and configured to create a chemical and physical barrier to elution of the rapamycin and the trichostatin A, the basecoat and the topcoat do not blend.
2. The medical device according to claim 1 , wherein the implantable structure comprises a stent.
3. The medical device according to claim 1 , wherein the implantable structure comprises a stent-graft.